文献速递眼底病与葡萄膜炎

111例新发急性Vogt-Koyanagi-Harada病接受静脉脉冲糖皮质激素治疗的临床特征与视力结局

Clinical features and visual outcomes of 111 patients with new-onset acute Vogt-Koyanagi-Harada disease treated with pulse intravenous corticosteroids.
PubMed 文献 · Br J Ophthalmol · 2018-04-17

本文回顾性分析了日本杏林眼科中心1999至2015年间111例新发急性Vogt-Koyanagi-Harada病患者的临床记录,所有患者初始均接受静脉脉冲糖皮质激素治疗。随访中位36个月,93%的眼在 presentation 后1年视力达≥1.0,22.5%的患者出现炎症复发,部分患者转换为环孢素治疗。

要点

  • 所有患者初始均接受静脉脉冲糖皮质激素治疗,部分病例转换为环孢素。
  • 1年时93%的眼(167/178眼)视力达≥1.0,复发率为22.5%。
  • 眼部并发症见于21.2%的眼(47/222眼),以白内障为主。

核心结论

  • 在新发急性Vogt-Koyanagi-Harada病患者中采用积极的糖皮质激素治疗策略,并在部分病例中转换为环孢素,可获得良好的视力结局和较低的复发率。

研究设计与样本

  • 回顾性审查1999至2015年间在东京杏林眼科中心眼炎症服务就诊的111例新发急性Vogt-Koyanagi-Harada病患者临床记录。
  • 111例患者中女性68例、男性43例;完全型VKH 16例、不完全型90例、可能型5例;就诊时平均年龄41岁(19-74岁)。
  • 中位随访36个月(4-175个月)。

主要发现

  • 就诊时观察到浆液性视网膜脱离(202眼)和视盘充血(89眼)。
  • 受检者中45/48(93.8%)为人类白细胞抗原-DR4阳性,63/77(81.8%)有脑脊液细胞增多。
  • 落日样眼底见于49.5%的眼,前节和/或后节炎症复发见于25例患者(22.5%)。
  • 17例患者(15.3%)转换为环孢素治疗,其中6例为减少激素用量、11例为复发性炎症,后续控制良好。
  • 眼部并发症见于47/222眼(21.2%),以白内障为主;全身并发症见于8.1%的患者,以高血压和糖尿病为主。

关键数值与推荐

  • 初诊时浆液性视网膜脱离202眼、视盘充血89眼。
  • 人类白细胞抗原-DR4阳性45/48(93.8%),脑脊液细胞增多63/77(81.8%)。
  • 落日样眼底49.5%的眼,炎症复发25例(22.5%)。
  • 转换为环孢素17例(15.3%):减少激素用量6例、复发性炎症11例。
  • 眼部并发症47/222眼(21.2%),全身并发症8.1%的患者;1年视力≥1.0者167/178眼(93%)。

临床怎么用

  • 所有患者初始治疗均为静脉脉冲糖皮质激素,部分病例转换为环孢素以节省激素或控制复发性炎症。
  • 作者报告该积极糖皮质激素治疗策略在大量新发急性VKH病患者中获得了良好的视力结局和较低的复发率。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To describe the clinical features, treatment and visual outcomes of Japanese patients with new-onset acute Vogt-Koyanagi-Harada (VKH) disease. METHODS: Clinical records of 111 patients who presented between 1999 and 2015 to the Ocular Inflammation Service of the Kyorin Eye Center, Tokyo, were reviewed. RESULTS: Of the 111 patients (68 women, 43 men), 16 had complete, 90 had incomplete and 5 had probable VKH disease. The median follow-up period was 36 months (4-175 months). The mean age at presentation was 41 years (19-74 years). Serous retinal detachment (202 eyes) and optic disc hyperaemia (89 eyes) were observed at presentation. Of the patients tested, 45/48 (93.8%) were human leucocyte antigen-DR4 positive and 63/77 (81.8%) had cerebrospinal fluid pleocytosis. Initial corticosteroid treatment consisted of pulse intravenous therapy in all patients. Sunset glow fundus was observed in 49.5% of eyes, and anterior and/or posterior segment recurrence of inflammation was observed in 25 patients (22.5%). Treatment was transitioned to cyclosporine in 17 patients (15.3%) for steroid sparing (6 patients) or recurrent inflammation (11 patients), with good subsequent control. Ocular complications were observed in 47 of 222 eyes (21.2%) (mostly cataract), and systemic complications were observed in 8.1% of patients (mostly hypertension and diabetes mellitus). Ninety-three percent of eyes (167 of 178 eyes) had a visual acuity of ≥1.0 at 1 year after presentation. CONCLUSIONS: An aggressive corticosteroid treatment strategy in a large number of patients with new-onset acute VKH disease, with transitioning to cyclosporine in selected cases, resulted in excellent visual outcomes and low rates of recurrence.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Nakayama M, Keino H, Watanabe T, et al. Clinical features and visual outcomes of 111 patients with new-onset acute Vogt-Koyanagi-Harada disease treated with pulse intravenous corticosteroids. Br J Ophthalmol. 2018. PMID: 29666121. doi:10.1136/bjophthalmol-2017-311691

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。